Skip to main content

Table 2 Clinicopathological variables and the expression of LINC00309 in HR-positive cases

From: LINC00309 is associated with short disease-free survival in breast cancer

Variables

Number of patients (%)

LINC00309 expression

pa value

Low n (%)

High n (%)

Total

161

70 (43.5)

91 (56.5)

 

Age

0.942

 ≤ 40 years

28 (17.4)

12 (7.5)

16 (9.9)

 

 > 40 years

133 (82.6)

58 (36.0)

75 (46.6)

 

Tumor size

0.552

 T1

59 (36.6)

23 (14.3)

36 (22.4)

 

 T2

96 (59.6)

45 (28.0)

51 (31.7)

 

 T3

6 (3.7)

2 (1.2)

4 (2.5)

 

Lymph node status

0.824

 pN0

69 (42.9)

31 (19.3)

38 (23.6)

 

 pN1

45 (28.0)

19 (11.8)

26 (16.1)

 

 pN2

21 (13.0)

9 (5.6)

12 (7.5)

 

 pN3

25 (15.5)

10 (6.2)

15 (9.3)

 

 Unknown

1 (0.6)

1 (0.6)

0 (0.0)

 

Vessel invasion

0.708

 Negative

87 (54.0)

39 (24.2)

48 (29.8)

 

 Positive

74 (46.0)

31 (19.3)

43 (26.7)

 

HER-2/neu status

0.011

 Negative

120 (74.5)

46 (28.6)

74 (46.0)

 

 Positive

36 (22.4)

19 (11.8)

17 (10.6)

 

 Unknown

5 (3.1)

5 (3.1)

0 (0.0)

 

Ki-67 status

0.489

 Negative

108 (67.1)

49 (30.4)

59 (36.6)

 

 Positive

53 (32.9)

21 (13.0)

32 (19.9)

 

Chemotherapy regimes

0.271

 CAFb

30 (18.6)

15 (9.3)

15 (9.3)

 

 TC (± H)c

11 (6.8)

2 (1.2)

9 (5.6)

 

 CAF-T (± H)d

85 (52.8)

39 (24.2)

46 (28.6)

 

 Other

6 (3.7)

4 (2.5)

2 (1.2)

 

 None

20 (12.4)

6 (3.7)

14 (8.7)

 

 Unknown

9 (5.6)

4 (2.5)

5 (3.1)

 

Hormone therapy

0.358

 SERMs related

62 (38.5)

25 (15.5)

37 (23.0)

 

 TAM only

38 (23.6)

14 (8.7)

24 (14.9)

 

 TAM + LHRH

6 (3.7)

1 (0.6)

5 (3.1)

 

 TAM (major)-AIse

6 (3.7)

3 (1.9)

3 (1.9)

 

 Othersf

12 (7.5)

7 (4.3)

5 (3.1)

 

 AIs related

75 (46.6)

31 (19.3)

44 (27.3)

 

 AIs only

60 (37.3)

25 (15.5)

35 (21.7)

 

 AIs + LHRH

3 (1.9)

1 (0.6)

2 (1.2)

 

 TAM-AIs (major)g

9 (5.6)

5 (3.1)

4 (2.5)

 

 AIs-othersh

3 (1.9)

0 (0.0)

3 (1.9)

 

 Unknown

24 (14.9)

14 (8.7)

10 (6.2)

 
  1. HR hormone-receptor, HER-2 human epidermal growth factor receptor 2, SERMs selective estrogen receptor modulators, TAM tamoxifen, LHRH luteinizing hormone releasing hormone, AIs aromatase inhibitors
  2. ap is based on Pearson’s χ2 or Fisher’s exact tests
  3. bAnthracycline plus cyclophosphamide and 5-fluorouracil
  4. cTaxanes plus cyclophosphamide combined with herceptin or not
  5. dAnthracycline-based chemotherapy followed by taxanes combined with herceptin or not
  6. eThe time patient took tamoxifen longer than the time to take AIs in tamoxifen followed by AIs regime
  7. fRaloxifene related, including raloxifene only and raloxifene mainly strategies
  8. gThe time patient took tamoxifen shorter than the time to take AIs in tamoxifen followed by AIs regime
  9. hThe time patient took AIs longer than the time to take fulvestrant in AIs followed by fulvestrant regime